Translational applications of adult stem cell-derived organoids

Drost, Jarno; Clevers, Hans

doi:10.1242/dev.140566

Cited by 113 publications

(88 citation statements)

References 88 publications

(119 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, for organoid cell therapy to be cost-effective, it will be crucial to determine whether, after being expanded in culture, organoid cells still retain the HLA type of the original patient, which would result in the abolition of any immunosuppressive treatment post-transplantation and be a clear benefit for the patient and the healthcare systems. For details on the translational applications of organoids, see Drost and Clevers (2017) in this issue.…”

Section: Organoids As Disease Models and Their Medical Applicationsmentioning

confidence: 99%

The hope and the hype of organoid research

et al. 2017

View full text Add to dashboard Cite

The recent increase in organoid research has been met with great enthusiasm, as well as expectation, from the scientific community and the public alike. There is no doubt that this technology opens up a world of possibilities for scientific discovery in developmental biology as well as in translational research, but whether organoids can truly live up to this challenge is, for some, still an open question. In this Spotlight article, Meritxell Huch and Juergen Knoblich begin by discussing the exciting promise of organoid technology and give concrete examples of how this promise is starting to be realised. In the second part, Matthias Lutolf and Alfonso Martinez-Arias offer a careful and considered view of the state of the organoid field and its current limitations, and lay out the approach they feel is necessary to maximise the potential of organoid technology.

show abstract

Section: Organoids As Disease Models and Their Medical Applicationsmentioning

confidence: 99%

The hope and the hype of organoid research

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Thus, while collecting material for tumour characterisation, some tissue or surgical aspirate should also be collected to establish cell or organoid cultures, or animal models. 58 In addition to the requirements of ongoing exploratory and validation research, biological data will also be needed for future diagnostic re-evaluations. Especially in long-duration clinical trials, relevant knowledge about diagnostic groups and host factors (eg, cancer predisposition or genotype variants affecting treatment efficacy) can sometimes be improved between the time of patient inclusion and data analysis.…”

Section: Need For Tumour Tissue For Precision Medicinementioning

confidence: 99%

Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group

Rutkowski

Modena

Williamson

et al. 2018

The Lancet Oncology

View full text Add to dashboard Cite

Paediatric CNS tumours are the most common cause of childhood cancer-related morbidity and mortality, and improvements in their diagnosis and treatment are needed. New genetic and epigenetic information about paediatric CNS tumours is transforming the field dramatically. For most paediatric CNS tumour entities, subgroups with distinct biological characteristics have been identified, and these characteristics are increasingly used to facilitate accurate diagnoses and therapeutic recommendations. Future treatments will be further tailored to specific molecular subtypes of disease, specific tumour predisposition syndromes, and other biological criteria. Successful biomaterial collection is a key requirement for the application of contemporary methodologies for the validation of candidate prognostic factors, the discovery of new biomarkers, the establishment of appropriate preclinical research models for targeted agents, a quicker clinical implementation of precision medicine, and for other therapeutic uses (eg, for immunotherapies). However, deficits in organisational structures and interdisciplinary cooperation are impeding the collection of high-quality biomaterial from CNS tumours in most centres. Practical, legal, and ethical guidelines for consent, storage, material transfer, biobanking, data sharing, and funding should be established by research consortia and local institutions to allow optimal collection of primary and subsequent tumour tissue, body fluids, and normal tissue. Procedures for the collection and storage of biomaterials and related data should be implemented according to the individual and organisational structures of the local institutions.

show abstract

“…The power of organoids lies in their ability to be cultured from human patient-derived adult tissue-resident stem cells (ASCs) or pluripotent stem cells (PSCs), paving the way for personalised medicine and primary tissue disease modelling [18,19]. Although, as with any model, organoids are not without limitations (See Text box: 'Don't believe the hype: organoid limitations').…”

Section: What Can Organoids Do For You?mentioning

confidence: 99%

Diabetes through a 3D lens: organoid models

2020

View full text Add to dashboard Cite

Diabetes is one of the most challenging health concerns facing society. Available drugs treat the symptoms but there is no cure. This presents an urgent need to better understand human diabetes in order to develop improved treatments or target remission. New disease models need to be developed that more accurately describe the pathology of diabetes. Organoid technology provides an opportunity to fill this knowledge gap. Organoids are 3D structures, established from pluripotent stem cells or adult stem/progenitor cells, that recapitulate key aspects of the in vivo tissues they mimic. In this review we briefly introduce organoids and their benefits; we focus on organoids generated from tissues important for glucose homeostasis and tissues associated with diabetic complications. We hope this review serves as a touchstone to demonstrate how organoid technology extends the research toolbox and can deliver a step change of discovery in the field of diabetes.

show abstract

Translational applications of adult stem cell-derived organoids

Cited by 113 publications

References 88 publications

The hope and the hype of organoid research

The hope and the hype of organoid research

Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group

Diabetes through a 3D lens: organoid models

Contact Info

Product

Resources

About